Ionis Pharmaceuticals: Valuation Reassessed After Strong Shareholder Returns

Ionis Pharmaceuticals' (IONS) shares have gained 1.7% in the past day and 149.8% in the past year, with a 12.8% return over the past 3 months. The stock is currently trading at $81.66, below the average analyst price target of $89.40. The company's strong revenue growth and positive launch trajectory for Tryngolza and Donidalorsen are expected to drive sustained revenue increases and operating leverage. The narrative suggests that Ionis is undervalued, with a fair value of $89.40.